The presented case report concerns a 62-year-old male patient who was admitted to the rheumatology department with a fever, shoulder and hip joint pain, significant limitation of movement in these joints and general weakness. Laboratory test revealed increase of inflammatory parameters, as ESR and C-reactive protein, rheumatoid factor and ACPA antibodies were absent. In the course of diagnostics, infections and cancer were excluded. The patient met the classification criteria for polymyalgia rheumatica. Polymyalgia rheumatica is not a rare disease, but the number of elderly people in the world continues to increase, and we can assume that the prevalence of this disease will increase in the coming years. At suspicion on polymyalgia rheumatica, it is necessary to exclude other rheumatic diseases, infections and malignant neoplasms. The authors also presented which diseases should be considered in the differential diagnosis.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6052374PMC
http://dx.doi.org/10.5114/reum.2018.76906DOI Listing

Publication Analysis

Top Keywords

polymyalgia rheumatica
16
case report
8
polymyalgia
4
report polymyalgia
4
rheumatica
4
rheumatica presented
4
presented case
4
report concerns
4
concerns 62-year-old
4
62-year-old male
4

Similar Publications

[Rheumatology: what's new in 2024].

Rev Med Suisse

January 2025

Service de rhumatologie, HFR Fribourg, 1708 Fribourg.

In 2024, CD19-CAR T cells are ubiquitous in rheumatology, with incredible therapeutic results in cases of severe and refractory disease. This major advance confirms the interest of the B lymphocyte as a therapeutic target, and also suggests the real possibility of a drug-free remission, at the price of minor and minimal side effects for the time being. However, the necessary perspective is still lacking for a therapy that remains out of reach because of its price.

View Article and Find Full Text PDF

Objective: An unmet need exists for glucocorticoid-sparing treatments for patients with polymyalgia rheumatica (PMR). The antibody-drug conjugate ABBV-154 comprises adalimumab conjugated to a glucocorticoid receptor modulator. We evaluated ABBV-154 versus placebo in patients with glucocorticoid-dependent PMR.

View Article and Find Full Text PDF

Shoulder Injury Related to Vaccine Administration (SIRVA) is a complication caused by improperly administered vaccinations. It triggers an inflammatory cascade that damages shoulder structures, resulting in prolonged shoulder pain and restricted range of motion. Common diagnoses in SIRVA patients include shoulder bursitis (all classified as subacromial bursitis), adhesive capsulitis, and rotator cuff injuries such as tears or tendinopathy.

View Article and Find Full Text PDF

Objectives: This study aimed to describe the characteristics, inflammatory markers as surrogates for disease activity, and treatment of patients with polymyalgia rheumatica (PMR) in Japan.

Methods: This cohort study analysed the data of 373 patients with PMR retrieved from an electronic medical records database in Japan. Patients were classified into quartiles, based on the daily glucocorticoid dose over the initial 90 days of treatment (Q1-Q4).

View Article and Find Full Text PDF

A glucocorticoid-free era for polymyalgia rheumatica: are we on the brink of change?

Lancet Rheumatol

January 2025

Department of Rheumatology, Hospital of Brunico, Teaching Hospital of the Paracelsius Medical University, Brunico 39031, Italy; Division of Rheumatology and Clinical Immunology, Department of Internal Medicine, Medical University, Graz, Austria. Electronic address:

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!